Antiretroviral drugs and acute pancreatitis in HIV/AIDS patients: is there any association? A literature review

Drogas antirretrovirais e pancreatite aguda em pacientes com HIV/AIDS: existe alguma associação? Revisão da literatura

Natalia Mejias Oliveira¹, Felipe Augusto Yamauti Ferreira¹, Raquel Yumi Yonamine¹, Ethel Zimberg Chehter¹

ABSTRACT

In HIV-seropositive individuals, the incidence of acute pancreatitis may achieve 40% per year, higher than the 2% found in the general population. Since 1996, when combined antiretroviral therapy, known as HAART (highly active antiretroviral therapy), was introduced, a broad spectrum of harmful factors to the pancreas, such as opportunistic infections and drugs used for chemoprophylaxis, dropped considerably. Nucleotide analogues and metabolic abnormalities, hepatic steatosis and lactic acidosis have emerged as new conditions that can affect the pancreas. To evaluate the role of antiretroviral drugs to treat HIV/AIDS in a scenario of high incidence of acute pancreatitis in this population, a systematic review was performed, including original articles, case reports and case series studies, whose targets were HIV-seropositive patients that developed acute pancreatitis after exposure to any antiretroviral drugs. This association was confirmed after exclusion of other possible etiologies and/or a recurrent episode of acute pancreatitis after re-exposure to the suspected drug. Zidovudine, efavirenz, and protease inhibitors are thought to lead to acute pancreatitis secondary to hyperlipidemia. Nucleotide reverse transcriptase inhibitors, despite being powerful inhibitors of viral replication, induce a wide spectrum of side effects, including myelotoxicity and acute pancreatitis. Didanosine, zalcitabine and stavudine have been reported as causes of acute and chronic pancreatitis. They pose a high risk with cumulative doses. Didanosine with hydroxyurea, alcohol or pentamidine are additional risk factors, leading to lethal pancreatitis, which is not a frequent event. In addition, other drugs used for prophylaxis of AIDS-related opportunistic diseases, such as sulfamethoxazole-trimethoprim and pentamidine, can produce necrotizing pancreatitis. Despite comorbidities that can lead to pancreatic involvement in the HIV/AIDS population, antiretroviral drug-induced pancreatitis should always be considered in the diagnosis of patients with abdominal pain and elevated pancreatic enzymes.

Keywords: Pancreatitis/complications; Pancreatitis/etiology; Pancreatitis/epidemiology; Antiretroviral therapy, highly active/methods; Antiretroviral therapy, highly active/adverse effects; HIV; Acquired immunodeficiency syndrome

RESUMO

Em HIV-soropositivos, a incidência de pancreatite aguda pode chegar até 40% ao ano, o que é consideravelmente maior que na população geral, cuja incidência é de 2%. A partir de 1996, com a introdução da terapia antirretroviral combinada, conhecida pela sigla HAART (highly active antiretroviral therapy), o espectro de fatores nocivos ao pâncreas, como infecções oportunistas e uso de drogas para sua quimioprofilaxia, diminuiu consideravelmente. Análogos nucleotídios e anormalidades metabólicas, esteatose hepática e acidose láctica despontaram como novas condições que podem acometer o pâncreas. A fim de avaliar o papel das drogas antirretrovirais para tratamento do HIV/AIDS na incidência elevada de pancreatite aguda nessa população, foi realizada revisão sistemática, com inclusão de artigos originais, relatos e séries de caso, cujos alvos de estudo eram pacientes HIV-soropositivos que evoluíram com pancreatite aguda após exposição a alguma das drogas que compõem o esquema antirretroviral. Essa associação foi confirmada após exclusão de outras possíveis etiologias e/ou recorrência do episódio de pancreatite aguda após reexposição ao fármaco suspeito. Zidovudina, efavirenz e os inibidores de protease são suspeitos de levar a uma pancreatite secundária à hiperlipidemia. Já os análogos nucleotídios da transcriptase reversa, apesar de serem...
In the pre-HAART era, pentamidine and didanosine, drugs extensively used for AIDS patients, were associated with increased incidence of AP, mainly when there was a previous episode of AP, prolonged treatment with high doses and severe immunocompromised conditions. In the Cappell and Marks series, among 18 patients with drug-related AP, pentamidine was responsible for 12 cases, followed by didanosine with 4, and sulfamethoxazole-trimethoprim with 2 cases. When compared to the control group, these patients were younger (mean age of 35.2 years versus 49.1 years) and, generally, men (77% versus 48%) and black individuals (77% versus 11%).

Despite the evidence, HIV/AIDS patients may present a wide range of toxic factors to the pancreas, such as opportunistic infections by *Pneumocystis jiroveci* and *Mycobacterium avium* complex, neoplasms and metabolic changes due to use of antiretroviral drugs. With the introduction of HAART and consequent reduction in the need for treatment and chemoprophylaxis for opportunistic infections, the administration of combined antiretroviral agents and metabolic abnormalities, such as liver steatosis and lactic acidosis, emerged as new conditions affecting the pancreas. Thus, acknowledging that: drug induced AP occurs after beginning treatment with a certain drug; that the resolution of the clinical picture occurs with withdrawal of treatment; and that the condition returns with the re-administration of medication, without other apparent causes of pancreatitis the objective of the present study was to assess the role of the most common antiretroviral drugs used to treat HIV/AIDS individuals in the development of episodes of AP, mainly after 1996, when the HAART regimen began to be used routinely.
criteria. The study was considered non-eligible, when it was not the subject of interest and/or it met exclusion criteria. The authors collected data, such as study population and associated risk factors, exposure or not to antiretrovirals, definition of AP used by the authors and, finally, the conclusion of the study on the relation between AP and the HAART regimen. Then, the methodological quality was assessed and results were analyzed independently. In case of disagreements, the classification of the studies was discussed in a meeting to establish a consensus among authors.

Thus, the authors selected original articles, reports and case series that aimed to study HIV-positive patients that developed AP after exposure to any of the drugs in the HAART regimen, and that had this association confirmed after ruling out other possible etiologies and/or recurrence of the AP episode after re-exposure to the suspected drug.

Abdominal pain associated with high pancreatic enzymes (amylase and lipase) three times above the upper normal limit, and abnormalities observed on the ultrasound and/or CT scan were considered AP.

All drugs comprising any HIV/AIDS treatment regimen were also considered: nucleotide reverse-transcriptase inhibitors (NRTI), non-nucleoside reverse-transcriptase inhibitors (NNRTI) and proteases inhibitors (PI).

Articles not published in portuguese, english and spanish; articles that did not explicit diagnostic criteria of AP; studies conducted exclusively before 1996 when the concept of combined antiretroviral therapy (HAART) was introduced; and articles that only related HIV/AIDS with non-specific pancreatic alterations were excluded.

The quality of studies was assessed using a Delphi list, using nine questions with three possible answers (yes, no and do not know), as internal and external validity, and statistical considerations.

RESULTS

We identified 64 articles, 23 of which met selection criteria. The studies included in the review are represented in charts 1 and 2.

After 1996, there was an increase in cases of AP attributed to drugs, mainly to combined antiretroviral therapy and not to a specific drug. A study from South Africa(35) found an incidence of 5% for antiretroviral-

| Chart 1. Association of antiretroviral drugs, comorbidities and acute pancreatitis in selected case reports |
|---------------------------------------------------------------|
| **Author/year/origin** | **Antiretroviral regimen** | **Comorbidities/ associated conditions** | **Re-exposure to a suspected drug (yes/no)** | **Is AP associated to HAART?** |
| Allaouchiche et al. (24), 1999, France | Didanosine, stavudine, indinavir | Kaposi sarcoma, lactic acidosis | No | No, presence of other conditions |
| Sarner & Fakoya (25), 2002, England | Stavudine, didanosine, nevirapine (2 cases) | Case 1: pregnant woman 37 weeks, HELLP and treated tuberculosis | No | Case 1: No, presence of lactic acidosis and HELLP |
| Case 2: pregnant woman 33 weeks | No | Case 2: yes |
| Kirian et al. (26), 2004, United States | Didanosine (low dosage), tenofovir, lamivudine, stavudine, efavirenz | Hypertriglyceridemia, diabetes mellitus, prophylaxis of opportunistic infections | No | Yes, probably association of tenofovir and didanosine |
| Blanchard et al. (27), 2003, United States | Didanosin and tenofovir in common + other antiretroviral (4 cases) | Low CD4 count, associated opportunistic infections, cholelithiasis, hyperlipidemia, marked weight loss | No | Yes, tenofovir and didanosine |
| Callens et al. (28), 2003, Belgium | Zidovudine, ritonavir | No description | No | Yes |
| Longhurst & Pinching (29), 2001, England | Estavudina, didanosina, nevirapina | Association with hydroxyurea | No | Yes, ritonavir due to induction of hypertriglyceridemia |
| Mirete et al. (30), 1998, Colombia | Zidovudina, ritonavir | No description | No | 55m |
| Perry et al. (31), 1999, United States | Ritonavir, saquinavir, zidovudine, lamivudine, delavirdine | Hypertriglyceridemia | Yes | Yes, ritonavir due to induction of hypertriglyceridemia |
| Di Martino et al. (32), 1999, France | Zidovudine, nevirapina | No description | Yes | Yes |
| Chapman et al. (33), 2007, England | Tenofovir, zidovudine, lamivudine, abacavir, tipranavir, ritonavir | Alcohol abuse, associated opportunistic infections | No | Yes, tipranavir and ritonavir due to induction of hypertriglyceridemia |
| Trinidad et al. (34), 2008, United States | Abacavir, lamivudine | Familial hypertriglyceridemia, estrogen therapy, prophylaxis of opportunistic infections | No | No, presence of other conditions that led to AP |

AP: acute pancreatitis, HAART: highly active antiretroviral therapy.
Chart 2. Characteristics, mains risk factors and antiretroviral drugs related to acute pancreatitis in selected studies

| Author/year/origin | Type of study/period | n | Etiology/risk factors | Main antiretroviral associate dto AP | Is AP associated to HAART? |
|--------------------|----------------------|---|-----------------------|-------------------------------------|---------------------------|
| Anderson et al.(35), 2008, South Africa | Prospective cohort (2001-2006) | 282 | Alcohol (62%), biliary (14%), dyslipidemia (8%), antiretroviral agents (5%) | Didanosine, stavudine | Yes |
| Moore et al.(36), 2001, United States | Prospective | 2,613 (33 cases of AP) | Hyponatremia, female gender, past history of AP, CD4 count <200 cells/mm³ | Didanosine with hydroxyurea | Yes |
| Gan et al.(2), 2003, Canada | Prospective | 73 | AIDS, severe immunosuppression | Didanosine in different regimes | Yes; 46% of AP due to drugs; polypharmacy |
| Manfredi et al.(39), 2004, Italy | Case control | 920 (128 cases of AP) | Alcohol, opportunistic infections and prophylaxis, liver or biliary diseases, PI, hypertriglyceridemia | Didanosine, stavudine, lamivudine, PI | Yes |
| Riedel et al.(38), 2008, United States | Case control (1996-2006) | 5,970 (65 cases of AP) | Females, CD4 count <50 cells/mm³, stavudine and pentamidine | Stavudine | Yes |
| Guo et al.(40), 2005, United States | Retrospective (1997-2002) | 4,972 (159 cases of AP) | Non-Caucasian, advanced age, AIDS, liver and cardiovascular diseases | Didanosine with NRTI or NNRTI or PI | No |
| Reisler et al.(33), 2006, United States | 20 clinical studies (1989-1999) | 8,461 (incidence of AP of 2.23 cases/100) | - | Didanosine, stavudine and indinavir with or without hydroxyurea | Yes |
| Smith et al.(41), 2006, England | Retrospective (2001-2006) | 9,678 (43 cases of AP) | Low CD4 count | Didanosine, stavudine | No |
| Barrios et al.(42), 2004, United States | Prospective | 309 | - | Didanosine, tenofovir, efavirenz | No; there were no cases of AP or neuropathy |
| Martinez et al.(43), 2004, Spain | Retrospective (2001-2003) | 575 (6 cases of AP) | - | Didanosine and tenofovir | Yes; greater incidence when associated |
| Bush et al.(44), 2003, United States | Retrospective (1990-2001) | 250 (84 cases of AP) | Alcohol, opportunistic infections | Didanosine, stavudine, lamivudine, zalcitabine, PI | Incidence of AP did not change after PI introduction |
| Manfredi e Calza(45), 2008, Italy | Prospective cohort (2005-2006) | 1,081 | Time of HIV infection, AIDS, hepatobiliary disease, hypertriglyceridemia, alcohol, illicit drugs, prophylaxis of opportunistic infections | Didanosine, stavudine, lamivudine, PI | Yes |

AP: acute pancreatitis. HAART: highly active antiretroviral therapy; PI: protease inhibitors; NRTI: nucleoside reverse transcriptase inhibitors; NNRTI: non-nucleoside reverse transcriptase inhibitors.

related AP, especially didanosine and stavudine. However, like in the general population, the main cause of AP remained alcohol abuse, followed by AP of biliary origin.

Trivedi et al.(2) selected the one hundred most prescribed drugs by physicians in the United States, evaluating their association with AP. Didanosine, with 883 cases reported and 9 cases after re-exposure, was the main drug associated with AP. Moreover, in class I (at least 20 AP cases reported), we found pentamidine and sulfamethoxazole-trimethoprim. In class II (between 10 and 20 reports of AP), was lamivudine, while in class III (at least 1 case of AP), were most of the drugs used in the HAART regimen, such as abacavir, stavudine, zidovudine, indinavir, ritonavir, efavirenz, among others.

Didanosine, alone or in different combinations (didanosine/stavudine/indinavir; didanosine/stavudine/nevirapine; didanosine/tenofovir), was strongly associated with medication-induced AP.(24-29,47)

A study conducted by Moore et al.,(36) analyzed 2,613 patients on treatment with 6 different NRTI regimens. The incidence of AP was lower among those who used only zidovudine, didanosine or stavudine, while the group on didanosine associated with hydroxyurea, to boost action, had an increased risk, possibly because of increased mitochondrial dysfunction. On the other hand, the concomitant use of PI or NNRTI did not increase the risk for AP.

Gan et al.,(37) analyzed 73 men infected by the HIV virus that developed AP, between 1989 and 1999, and observed that the most frequent etiology (46%) was
drug related, mainly with didanosine and pentamidine. A peak in the incidence of AP in the mid 1990’s, with a trend towards a fall in the following years, probably represents a change in the practice of prescribing didanosine.

After the introduction of HAART, Manfredi et al.\(^ {38}\) expected changes in HIV-related pancreatic abnormalities. Among 334 patients with a single episode of laboratory abnormal pancreatic enzymes, no relation was established between the duration of the administration of nucleoside analogues and AP. However, prolonged abnormal pancreatic enzymes, with or without clinical manifestations, occurred in 128 patients, and were attributed to the ongoing administration of didanosine, stavudine, PI, pentamidine, lamivudine, sulfamethoxazole-trimethoprim or anti-tuberculosis therapy, alcohol abuse, opportunistic infections, chronic hepatobiliary disease and hypertriglyceridemia.

According to a study performed by Riedel et al.\(^ {39}\) at the Johns Hopkins Hospital, between 1996 and 2006, the incidence of AP that required admission to hospital was ten-fold higher among HIV patients than in the general population. However, there were no significant differences between incidence of AP in the pre and post-HAART eras, with a slighter lower number of hospitalizations in the HAART era attributed to less use of some NRTI (didanosine and stavudine) and hydroxyurea. PI or NNRTI were not associated with increased rates of AP, as the most recent antiretroviral drugs (atazanavir, ritonavir, tenofovir, abacavir or efavirenz).\(^ {39}\)

Guo et al.\(^ {40}\) on the other hand, after a retrospective study of 4972 patients with HIV infection, found 159 cases of AP, most of which in patients who had begun treatment recently. However, the risk did not change for patients on different treatment antiretroviral regimens, including use of didanosine.

In a study with about 3000 patients, the combination of selected NRTI impacted on the incidence of AP (0.85/100 persons/year).\(^ {41}\) Despite major differences in several arms of the study, didanosine/stavudine was observed to be associated with the highest rates of the condition. In protocols that included PI, combining nevirapine or indinavir with nucleosides, the incidence of AP was similar to groups that used exclusively nucleosides. In this scenario, the association indinavir/didanosine/stavudine was the regimen that resulted in the highest rates of pancreatitis due inducing metabolic and lipid alterations at the cell level, in addition to leading to microlithiasis, resulting in biliary pancreatitis.

The presence of hydroxyurea did not significantly change pancreatitis rates, having been similar for patients on didanosine/hydroxyurea and only on didanosine. In contrast, the frequency of didanosine-induced AP seemed to dose-dependent and related to its high plasma concentration, mainly when taken along with tenofovir\(^ {41}\).

The multicenter EuroSIDA\(^ {42}\) study observed a low incidence of pancreatitis among patients with HIV/AIDS. Although a great part of these patients had contact with NRTI at some point before developing AP, the investigators did not find a relation of the disease with a specific antiretroviral drug or combination of them.

Another two studies tried to assess safety and efficacy of administering didanosine and tenofovir. In the first study, 309 patients had their antiretroviral regimen replaced by didanosine, tenofovir and efavirenz. After 6 months, no event of AP or neuropathy was observed.\(^ {43}\) In the second study, 185 patients were studied after the prescription of didanosine (250 or 400mg), tenofovir and a third unspecified drug. Five female low-body weight patients (47-56kg) developed AP after a mean of 22 weeks of treatment.\(^ {44}\) The study also concluded that lower doses of didanosine, when associated with tenofovir, may help keep safe therapeutic levels, without increasing morbidity.

Similar to Riedel et al.\(^ {39}\) and Reisler et al.\(^ {41}\), Bush and Kosmiski\(^ {45}\) pointed out that neither PI or NNRTI led to a true increase in the incidence of AP, despite initial fears and reports of PI-induced hypertriglyceridemia.

Another study, performed by Manfredi and Calza\(^ {46}\) observed a high incidence and longer duration of pancreatic abnormalities in patients with long-term PI administration (over 6 months), parallel to existing hypertriglyceridemia. In some cases, the severe picture of AP is attributed to hypertriglyceridemia;\(^ {19,30,31}\) in others, it occurred after re-exposure to the medication, without rise in triglycerides.\(^ {45}\)

Chapman\(^ {33}\) reported a case of a patient with previous opportunistic infections and a history of alcohol abuse who developed a hypertriglyceridemia-induced AP and that resolved after interruption of tipranavir and ritonavir. Trindade et al.\(^ {34}\) described a HIV-infected woman with AP, on abacavir and lamivudine, which rarely leads to pancreatic lesion. There was however a family history of hypertriglyceridemia and use of estrogens and sulfamethoxazole-trimethoprim, also involved in episodes of AP.

Table 1 describes the main risk factors associated with AP in patients with HIV/AIDS on antiretroviral treatment.

---

einstein. 2014;12(1):112-9
DISCUSSION

The HIV infection becomes chronic if treatment begins in the initial stage and is taken without interruption. However, while antiretroviral treatment is highly efficacious, it is also very complex and dangerous, due to its toxic effects, including drug-induced pancreatitis. There is a wide range of factors that can affect the pancreas, from the direct lesion by the HIV, opportunistic infections and neoplasms, alcohol abuse and use of illicit drugs and antiretroviral drugs. As observed in several studies,\(^{36,36-40}\) HIV-positive patients that develop AP, in addition to exposure to the HAART regimen drugs, have in common advanced age, non-white race (risk 39 to 54% higher for non-whites compared to Caucasians), long duration of seropositivity, CD4 <200 cells/mm\(^3\), AIDS diagnosis, high viral load, previous history of AP, hepatobiliary diseases, opportunistic infection prophylaxis, alcohol abuse, in addition to, most of the time, women with a low body mass index (BMI) (more sensitive to toxic effects). That is exactly why it is difficult to evaluate the toxic effect of the HAART regimen on the pancreas.

Despite this, zidovudine, efavirenz and PI are suspected of leading to AP secondary to hyperlipidemia. NRTI, on the other hand, cause a series of side effects – among which myelotoxicity, lactic acidosis, polyneuropathy and AP. Didanosine, zalcitabine and stavudine were reported to lead to chronic and acute pancreatitis, with a high risk of cumulative dose. Didanosine with hydroxyurea, alcohol or pentamidine are additional risk factors, and may induce to lethal pancreatitis.

As part of HAART, PI have led to a significant decline in HIV-related morbidity and mortality.\(^{48}\) However, PI-based treatments are, in general, associated with changes in the distribution of body fat and with metabolic disorders, such as insulin resistance and hypertriglyceridemia.\(^ {21,49}\) The latter is usually severe and difficult to control, and may trigger episodes of AP. However, it must be taken into account that many patients do not have alternatives to PI, because the infection is resistant to other classes of antiretroviral drugs.\(^ {21}\)

Thus, many of the drugs prescribed in offices routinely are suspected of causing AP. However, drug-induced pancreatitis is frequently not acknowledged, because mild cases, with significant increases (but not critical) in amylase and lipase levels, may go unnoticed, in addition to the possible dissociation at the time of exposure to the drug and the development of AP. This condition can also be confounded with alcohol-induced or biliary pancreatitis, and there are no features to differentiate them. Therefore, physicians should be highly suspicious, mainly in patients that use several drugs simultaneously.

In this context, it is essential to acknowledge the adverse effects caused by HAART, aimed at improving tolerability and efficacy of treatment for HIV, promoting the early recognition and reversion of these potentially serious effects, and reducing the potential for adverse drug interactions.

However, more evidence is still necessary to determine if pancreatic morbidity is directly related to drugs used in HAART therapy or to other comorbidities.

CONCLUSION

Drug-induced pancreatitis triggered by antiretroviral drugs of the HAART regimen should always be considered in the differential diagnosis of HIV/AIDS patients that present with abdominal pain and high levels of pancreatic enzymes.
REFERENCES

1. Joint United Nations Programme on HIV/AIDS (UNAIDS). Global Report: UNAIDS report on the global AIDS epidemic. 2010. UNAIDS/10.11E/IC19568E. [cited 2013 Jun 2]. Available from: http://www.unaids.org/globalreport

2. Trivedi CD, Pitchumoni CS. Drug-induced pancreatitis: an update. J Clin Gastroenterol. 2005;39(8):709-16.

3. Brivet F, Coffin B, Bedossa P, Nauwaut S, Petitprez P, Delfraissy JF, et al. Pancreatic lesions in AIDS. Lancet. 1987;2(8558):570-1.

4. Bricaire F, Marche C, Zoubi D, Saimont AG, Regnier B. HIV and the pancreas. Lancet. 1988;(185755):65-6.

5. Dowell SF, Moore GW, Hutchins GM. The spectrum of pancreatic pathology in patients with AIDS. Mod Pathol. 1990;31(1):49-53.

6. Bonacini M. Pancreatic involvement in human immunodeficiency virus infection. J Clin Gastroenterol.1991;13(1):58-64.

7. Chicarino JM, Cuzzi T, Oliveira AV, Gueimaraes GM, Cavalcanti RV, Grinsztejn B, et al. Histopathologic findings in necropsy of endocrine glands in patients with AIDS (abstract). Int Conf AIDS. 1992;8(2):B112.

8. Klatt EC, Nichols L, Noguchi TT. Envolving trends revealed by autopsies of patients with acquired immunodeficiency syndrome. Arch Pathol Lab Med. 1994;118(9):884-90.

9. Chetverin V, Longo MA, Laudanna AA, Duarte M. Involvement of the pancreas in AIDS: a prospective study of 109 post-mortems. AIDS. 2000;14(13):1789-96.

10. Cappell MS, Marks M. Acute pancreatitis in HIV-seropositive patients: A case control study of 44 patients. Am J Med. 1995;98(3):243-8.

11. Tanowitz HB, Simon O, Wittner M. Gastrointestinal manifestations: medical management of AIDS patients. Med Clin North Am. 1992;76(1):45-62.

12. Wilcox CM, Forsmark CE, Grendell JH, Darragh TM, Cello JP. Cytomegalovirus-associated acute pancreatic disease in patients with acquired immune deficiency syndrome: report of two patients. Gastroenterology. 1990;99(1):263-7.

13. Ortega GE, Martin HA, Lopez DM, Lellis FP, Ronda Gasulla FA, Gil Egea M, et al. Pancreatic disease in patients with HIV treated with didanosine (ddI). Rev Esp Enferm Dig. 1996;88(2):114-7.

14. Foisy MM, Slayter KL, Hewitt RG, Morse GD. Acute pancreatitis during intravenous pentamidina therapy in an AIDS patient with prior exposure to didanosine. Ann Pharmacother. 1994;28(9):1025-8.

15. Bouvet E, Casalino E, Prevost MH, Vachon F. Fatal case of 2',3' -dideoxyinosine-associated pancreatitis [Letter]. Lancet. 1990;336(8729):1515.

16. Aponte-Cipriani SL, Teplitz C, Yancovitz S. Pancreatitis possibly related to 2',3'-dideoxyctydine [Letter]. Ann Intern Med. 1993;119(6):539-40.

17. Maxson CJ, Greenfield SM, Turner JL. Acute pancreatitis as a common complication of 2',3'-dideoxythymidine therapy in the acquired immunodeficiency syndrome. Am J Gastroenterol. 1992;87(7):706-13.

18. Seidlin M, Lombart JS, Dolin R, Valentine FT. Pancreatitis and pancreatic dysfunction in patients taking dideoxyinosine. AIDS. 1992;6(8):831-5.

19. Pelucio MT, Rotthenhaus T, Smith M, Ward DJ. Fatal pancreatitis as a complication of therapy for HIV infection. J Emerg Med. 1995;13(5):633-7.

20. Cappell MS, Hasson T. Pancreatic disease in AIDS: a review. J Clin Gastroenterol. 1993;17(3):254-63.

21. Montessos V, Press N, Harris M, Akagi L, Montaner JS. Adverse effects of antiretroviral therapy for HIV infection. CMAJ. 2004;170(2):229-38.

22. Dutta SK, Ting CD, Lai LL. Study of prevalence, severity and etiological factors associated with acute pancreatitis in patients infected with human immunodeficiency virus. Am J Gastroenterol. 1997;92(11):2044-8.

23. Balani AR, Grendell JH. Drug-induced pancreatitis: incidence, management and prevention. Drug Saf. 2008;31(10):823-37.

24. Allaouchiche B, Duflo F, Cotte L, Mathon L, Chassard D. Acute pancreatitis with severe lactic acidosis in an HIV-infected patient on didanosine therapy. J Antimicrob Chemother. 1999;44(1):137-8.

25. Sarner L, Fakoya A. Acute onset lactic acidosis and pancreatitis in the third trimester of pregnancy in HIV-1 positive women taking antiretroviral medication. Sex Transm Infect. 2002;78(1):58-9.

26. Kriana MA, Higginson RT, Fuoco PD. Acute onset of pancreatitis with concomitant use of tenofovir and didanosine. Ann Pharmacother. 2004;38(10):1660-3.

27. Blanchard JN, Wohlfeller M, Canas A, King K, Longean JT. Pancreatitis with didanosine and tenofovir disoproxil fumarate. Clin Infect Dis. 2003;37(5):57-62.

28. Callens S, Schacht C, Huyst V, Colebunders R. Pancreatitis in a HIV-infected person on a tenofovir, didanosine and stavudine containing highly active antiretroviral treatment. J Infect. 2003;47(2):188-9.

29. Longhurst HJ, Pinching AJ. Drug points: pancreatitis associated with hydroxyurea in combination with didanosine. BMJ. 2001;322(7278):81.

30. Mirete G, Masia M, Gutiérrez F, Mora A, Escolano C, Maestro E. Acute pancreatitis as a complication of ritonavir therapy in a patient with AIDS. Eur J Clin Microbiol Infect Dis. 1998;17(11):810-1.

31. Perry RC, Cushing HE, Deeg MA, Prince MJ. Ritonavir, triglycerides, and pancreatitis. Clin Infect Dis. 1999;28(1):161-2.

32. Di Martino V, Ezenjis J, Benhamou Y, Bernard B, Opolon P, Bricaire F, et al. Severe acute pancreatitis related to the use of nelfinavir in HIV infection: report of a case with positive rechallenge. AIDS. 1999;13(11):1421-3.

33. Chapman SJ, Woolley LJ, Visvanathan K, Korman TM. Acute pancreatitis caused by tipranavir/ritonavir-induced hypertriglyceridaemia. AIDS. 2007;21(4):532-3.

34. Trindade AJ, Huysman A, Huprikar SS, Kim MK. A case study and review of pancreatitis in the AIDS population. Dig Dis Sci. 2008;53(10):2616-20.

35. Anderson F, Thomson SR, Clarke DL, Loots E. Acute pancreatitis: demographics, aetiological factors and outcomes in a regional hospital in South Africa. S Afr J Surg. 2008;46(3):83-6.

36. Moore RD, Keruly JC, Chaisson RE. Incidence of pancreatitis in HIV-infected patients receiving nucleoside reverse transcriptase inhibitor drugs. AIDS. 2001;15(5):617-20.

37. Gan I, May G, Raboud J, Tilley J, Enns R. Pancreatitis in HIV infection: predictors of severity. Am J Gastroenterol. 2003;98(6):1278-83.

38. Manfredi R, Calza L. A case-control study of HIV-associated pancreatic abnormalities during HAART era. Focus on emerging risk factors and specific management. Eur J Med Res. 2004;9(12):537-44.

39. Riedel DJ, Gebo KA, Moore RD, Lucas GM. A ten year analysis of the incidence and risk factors for acute pancreatitis requiring hospitalization in a urban HIV clinical cohort. AIDS Patient Care STDs. 2008;22(2):113-21.

40. Guo JJ, Jiang R, Louder A, Cluxton RJ. Acute pancreatitis associated with different combination therapies in patients infected with human immunodeficiency virus. Pharmacotherapy. 2005;25(8):1044-54.

41. Reisler RB, Murphy RL, Redfield RR, Parker RA. Incidence of pancreatitis in HIV-infected individuals enrolled in 20 adult AIDS clinical trials group studies: lessons learned. J Acquir Immune Defic Syndr. 2005;39(2):159-66.

42. Smith CJ, Olsen CH, Mocroft A, Viard JP, Staszewski S, Panos G, et al. The role of antiretroviral therapy in the incidence of pancreatitis in HIV-positive individuals in the EuroSIDA study. AIDS. 2008;22(11):47-56.

43. Barrios A, Negredo F, Vilaro-Rodriguez J, Domingo P, Estrada V, Labarga P, et al. Safety and efficacy of a QD simplification regimen. In: Proceedings of the 11th Conference on Retroviruses and Opportunistic Infections; 2004 February 8-11, San Francisco, United States of America: Foundation for Retrovirology and Human Health, 2004. Poster 566.

44. Martinez F, Milinkovic A, de Lazarraga F, Ravasti G, Blanco JL, Larrousse M, et al. Pancreatic toxic effects associated with co-administration of didanosine and tenofovir in HIV-infected adults. Lancet. 2004;364(9428):65-7.

45. Bush ZM, Kosmiski LA. Acute pancreatitis in HIV-infected patients: Are etiologies changing since the introduction of protease inhibitor therapy? Pancreas. 2003;27(1):e1-5.

46. Manfredi R, Calza L. HIV infection and the pancreas: risk factors and potential management guidelines. Int J STD AIDS. 2008;19(2):99-105.
47. Aboulafia DM. Acute pancreatitis: a fatal complication of AIDS therapy. J Clin Gastroenterol. 1997; 25(4):640-5.

48. Palella FJ Jr., Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338(13):853-60.

49. Safrin S, Grunfeld C. Fat distribution and metabolic changes in patients with HIV infection. AIDS. 1999;13(18):2493-505.